A board to discuss future MS therapies in early stage (Phase I or II) trials.


Postby bromley » Thu May 25, 2006 3:14 am


Trials not for MS, but something to keep in mind.


Synta launches human trials for anti-inflammatory drug

Synta Pharmaceuticals Corp. has launched two new midstage human clinical trials to test an anti-inflammatory drug.
The Lexington, Mass.-based private company said it had began dosing patients in two separate Phase II trials regarding the compound apilimod mesylate. One trial will focus on rheumatoid arthritis and the other will target common variable immunodeficiency, a condition that can lead to gastrointestinal complications.

Apilimod mesylate is designed to inhibit a family of proteins that cause inflammations in conditions including Crohn's disease, psoriasis, rheumatoid arthritis, multiple sclerosis and gastrointestinal problems from common variable immunodeficiency.

Source: Boston Business Journal © 2006 American City Business Journals, Inc. and its licensors. All rights reserved.
User avatar
Family Elder
Posts: 1888
Joined: Fri Sep 10, 2004 3:00 pm


Return to Drug Pipeline

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service